|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1989-12-15
|
|
pubmed:abstractText |
Twenty-seven patients with disseminated malignant melanoma were treated monthly with cisplatin (CDDP) 120 mg m-2 on day 1, vindesine (VDS) 3 mg m-2 on day 2 and dacarbazine (DTIC) 250 mg m-2 on days 2-6. None of them had received prior chemotherapy. All patients are evaluable for response and toxicity. There were five (19%) complete (CR) and seven (26%) partial (PR) responses for a total response rate of 45%. We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-2420443,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-266972,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-3621224,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-371802,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-393386,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-4842252,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-6168365,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-6174231,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-6196103,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-6199481,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-6362841,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-7459898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-769969,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2803936-769972
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
627-9
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2803936-Adult,
pubmed-meshheading:2803936-Aged,
pubmed-meshheading:2803936-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2803936-Cisplatin,
pubmed-meshheading:2803936-Dacarbazine,
pubmed-meshheading:2803936-Female,
pubmed-meshheading:2803936-Humans,
pubmed-meshheading:2803936-Lung Neoplasms,
pubmed-meshheading:2803936-Lymphatic Metastasis,
pubmed-meshheading:2803936-Male,
pubmed-meshheading:2803936-Melanoma,
pubmed-meshheading:2803936-Middle Aged,
pubmed-meshheading:2803936-Skin Neoplasms,
pubmed-meshheading:2803936-Vindesine
|
|
pubmed:year |
1989
|
|
pubmed:articleTitle |
Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
|
|
pubmed:affiliation |
Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Greece.
|
|
pubmed:publicationType |
Journal Article
|
